Crossmark

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review

Published Online: 2026-01-17

Published Print: 2026-02

Authors

Ábel, Tatjana

Benczúr, Béla

Csajbókné, Éva Csobod
Funding

Funding for this research was provided by:

Semmelweis University
License Information

Text and Data Mining valid from 2026-01-17

Version of Record valid from 2026-01-17
More Information

Article History

Received: 14 June 2025

Accepted: 27 September 2025

First Online: 17 January 2026

Declarations

:

: The authors declare no competing interests.

Document is current